GRIFFIN MICHELLE RENEE sold $1.1M of ADPT

GRIFFIN MICHELLE RENEE sold 52,084 shares of Adaptive Biotechnologies Corp (ADPT) at $20.18 ($1.05M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GRIFFIN MICHELLE RENEE
Published Jun 29, 2026, 11:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 11:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
medium confidence
Mentioned
$ADPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

A director’s open-market sale of $1.05M worth of shares under a pre-arranged 10b5-1 plan is typically not a strong standalone fundamental catalyst.

02

Market read

Traders may treat this as routine insider activity; any tradable signal is likely small unless it’s part of a broader pattern.

03

What to watch

The article doesn’t state total insider exposure changes beyond post-transaction holdings, nor whether other insiders filed around the same window.

Relevance 5/10Novelty 5/10Timing: SEC Form 4 filed 2026-06-29 (sale dated 2026-06-25)

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralMedium confidence
Context

Adaptive Biotechnologies director Griffin Michelle Renee sold 52,084 shares in an open-market transaction worth about $1.05M, per Form 4.

Expected impact

Low near-term impact; any reaction is likely muted unless follow-on insider activity accelerates.

Evidence & confidence

The filing is a Form 4 insider sale with a stated Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider liquidity rather than a regulatory/clinical/financing catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider sales can coincide with valuation or risk concerns; traders may watch for clustering of similar filings.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider sale disclosure.

  • GRIFFIN MICHELLE RENEE

    Director who sold 52,084 shares at $20.1800/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.